Q2e: 0% organic growth and stable margins Higher central costs behind 3-2% cuts to adj.
Researchers in China studying IRLAB’s lead asset, mesdopetam (IRL790) in a preclinical model for lev...
STENOCARE announced on June 17th that the company is planning an expansion into Canada together with...
Starkt kv2 2024 förväntas Fable Media Group AB (”FMG” eller ”Bolaget”) Meddelade på torsdagen den 1...
Under H1-24 har Luxbright AB (”Luxbright” eller ”Bolaget”) erhållit ordrar om ca 15 MSEK, och det ko...
Redeye leaves a comment following Magle’s announcement of an acquisition of pK Biotech ApS and its s...
Redeye comments on Lifecare after the announcement that its rights issue was oversubscribed, reinfor...
Redeye embraces the not-so-unanticipated SEK50m directed share issue, giving the company additional ...
Redeye expects a solid Q2 report from Proact, although we want to highlight that investors should no...
VEF är investmentbolaget som ger en unik möjlighet till att få exponering mot snabbväxande Fintech-b...
Ovzon-3 has reached its orbital position (5 months after launch) We expect orders picking up in H2.
Redeye comments on the outcome of Episurf Medical’s rights issue of units that secured the company S...
We expect the slow market to continue to impact Etteplan in 2024, while acquisitions support net sal...
Redeye in this note provides our first impressions on Acconeer’s CEO change that was announced yeste...
Redeye comments on recent news from Apple about its intention to open up its ecosystem to third-part...
We initiate coverage of Solwers, a company that acts as a growth platform for the built environment ...
Redeye makes a few comments following last week's hearing in Aequitas' patent lawsuit, which involve...
Med ett nytt godkännande i Danmark för en THC/CBD medicinsk cannabisolja har Stenocare återtagit pos...
CMS’ NTAP recommendation is positive, and we can expect a final decision by August, followed by a go...
Eastnine förvärvar en andra fastighet i polska Poznan och ökar hyresintäkterna med drygt 16% till 42...
